🔮 Forecasting the Uncertain: Mortality, Bleeding, and Ischemia in Cancer-Acute Coronary Syndromes

🧬⚖️ Cancer and Acute Coronary Syndromes: Precision Where It Matters Most   As cancer survival improves, more patients live long enough to face acute coronary syndromes (ACS)—often with competing risks of death, bleeding, and ischaemia. Yet these patients have been largely excluded from ACS trials, leaving clinicians to navigate uncertainty.   A landmark Lancet study introduces ONCO-ACS, the first cancer-specific, externally validated risk tool that simultaneously predicts 6-month mortality, major bleeding, and ischaemic events using 11 routine admission variables. 📊🧠 The result: actionable, bedside precision—helping tailor invasive strategy, antiplatelet intensity, and duration to the dominant risk for each patient.   This is a major step toward personalised cardio-oncology care, moving beyond one-size-fits-all scores to nuanced, patient-centred decisions. 🎯💡